Covid has proved we havent spent enough on life science research. Time to make up now – ThePrint

Text Size:A- A+

Indias life sciences sector, including pharmaceuticals, diagnostics, medical devices, clinical research, and digital health, has been at the forefront of our battle against the coronavirus pandemic. Domestic pharma companies are developing drugsandvaccines.Some have alsodeveloped testsand are rolling out testingservices. Indias hydroxychloroquine is being exported around theworldand is in great demandto aid the treatment of Covid patients.

Meanwhile, the Aarogya Setu contact tracing app has alreadyseenmore than 7.5 croredownloads.

We must now further strengthen the life sciences sector to meet the demands of the future. This will require a multi-dimensional approach.

Also read: To achieve herd immunity, vaccine and a data-driven approach needed: WHO chief scientist

First. There must beclose industry-government collaboration to develop and fine-tune regulations to promote fast growthfor the sector.

Second. We must ensure that we rapidly build up our life sciences workforce so that we can have enough talented people available for both the health care and the life sciencessectors.

Third. We should consider whether we are providing enough financial support for sectoral growth.

And, finally, we must leverage the fast-emerging IndianSuperCloudto connect all our life sciences activity.

Some of our life sciences enterprises are nowworld leaderssuch as Cipla, Aurobindo, Lupin, and DRL.Some 50per centof the worlds vaccines are produced in India. We also produce 20per centof the worlds generic medicines. The pharma industry alone generates close to $20 billion inannual exports.

Our skilled doctors, nurses, and other life sciences professionals are leading major research programmes in India and around the world. The coronavirus pandemic has proven to all of us that we have not been spending enough on life sciences and health care.

Resources and spending willneed togrow dramatically to protect the worlds population. Life sciences companies should now work closely with our various regulators and policy-makers throughempowered working groups to driveupinvestment, growth, and jobs.

Also read: Made-in-India Covid-19 vaccine could be ready in a year, says Biocons Kiran Mazumdar-Shaw

Life sciencesisa tightly regulated sector. In India, we have several regulators across multiple ministries that have oversight over the sector.

The National Pharmaceutical Pricing Authority (NPPA) sets prices for bulk drugs and formulations and is within the ministry of chemicals and fertilisers. The ministry of health and family welfare manages the safety, efficacy, and quality of drugs and medical devices through the Central Drugs Standard Control Organisation. In the same ministry, the National Health Portal of India is formulating Electronic Health Record (EHR) standards, which will also be governed by the Personal Data Protection bill, being handled by the ministry of electronics and information technology.

Alllife sciences research is conducted under the guidelines established by the Indian Council of Medical Research and the Ministry of Science & Technology. The Ayush Ministry and Niti Aayog also play an important role in the life sciences sector.Although healthis a state subject and each state can develop policies to support the sector,it is important thatall these regulators anddecision-makers,both at the centre and the state level, working with industry,developcoordinatedresponse forsectoral growth.

Also read: Covid-19 response is a chance for companies to place planet over profits

Along with deep collaboration between industry and government at all levels, we must also build up our life sciences workforce. Today we have 535 medical colleges in India graduating about 79,000 students every year. It is estimated that we currentlyhave 300,000 annualnursing seatsavailable. In addition, there are lakhs of biology, biotechnology, and chemistry students graduating every yearwhocan be employed in the life sciences sector.

That said, we still have only 0.7 doctors per 1,000 people against the minimumWorld Health Organizationsstandard of 1 per 1000 people. For nurses, we are at 1.7 when we should be at 2.5. In addition, we need to provide our educational institutions withsignificantly higherresearch funding so that we can get more young scientists and researchersto work towards developingcutting-edgesolutionsin drugs,devices, andtherapiessegments.

Also read: Critical drugs supply must not be disrupted, EU envoy says as India bans & resumes exports

Government funding worththousands of crores of rupees is required to drive this researchculture in India. An expert panel could be constituted to select 10-15 researchareassuch as genomics, computational biology, virology, epidemiology, neuroscience, stem cell research, etc.

Multi-year research grants could then be provided to top scientists (in India or from ourcommunity abroad) to pursue their research and train graduate students. Research productivity could then be judged on objective global metrics (high-quality citations, placement of graduate students in top institutions, and so on) to ensure accountability and quality.

We also need to back new life sciences enterprises with venture capital financing. The government has established a Rs 10,000 croreFund-of-Fundsto support venture capital funds. It might be possible to allocate a significant fraction of this money solely to life sciences funds, so that they can provide the necessary financing and support to life sciences startups. This will require that SIDBI have the necessary expertise toidentifyand nurture life sciences funds.

Also read: US drug authority warns Americans not to pop hydroxychloroquine pills without prescription

Finally, Indias fast-emerging SuperCloud can play an important role in the development of the life sciences sector. With high-speed 5G networks and local data centres, telemedicine and remote diagnostics will become fully feasible.

Theprovisions of thenew Personal Data Protection bill will make it possible to develop a secureelectronic health record (EHR)for every individual so that their necessary healthcare eligibility, data, and payments/insurance are available as required. Large local data lakes will enable AI and computational biology to develop therapies targeted for the Indian genome.

Pandemics will come and go,but ournon-communicable disease burden will continue to rise. Around the world, there is a looming shortage of skilled medical professionals and researchers. New, low-cost therapies are in high demand. The Indian life sciences sector can take advantageof these circumstancesto not only protect our health, but also become a growth engine for Indias economy.

Jayant Sinha is the Chairman of the Standing Committee on Finance in Parliament and a Lok Sabha MP from Hazaribagh, Jharkhand. These are his personal views.

ThePrint is now on Telegram. For the best reports & opinion on politics, governance and more, subscribe to ThePrint on Telegram.

Subscribe to our YouTube channel.

See more here:
Covid has proved we havent spent enough on life science research. Time to make up now - ThePrint

Potential Impact of COVID-19 on Induced Pluripotent Stem Cell Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 20582019-2019 – Jewish Life…

In 2018, the market size of Induced Pluripotent Stem Cell Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Induced Pluripotent Stem Cell market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Induced Pluripotent Stem Cell market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Induced Pluripotent Stem Cell market to assist our clients arrive at beneficial business decisions.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/17968

This study presents the Induced Pluripotent Stem Cell Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Induced Pluripotent Stem Cell history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Induced Pluripotent Stem Cell market, the following companies are covered:

Company Profile

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/17968

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Induced Pluripotent Stem Cell product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Induced Pluripotent Stem Cell, with price, sales, revenue and global market share of Induced Pluripotent Stem Cell in 2017 and 2018.

Chapter 3, the Induced Pluripotent Stem Cell competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Induced Pluripotent Stem Cell breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/17968

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Induced Pluripotent Stem Cell market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Induced Pluripotent Stem Cell sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read more here:
Potential Impact of COVID-19 on Induced Pluripotent Stem Cell Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 20582019-2019 - Jewish Life...

UW-Madison: Academy adds new members from UW who ‘expand the boundaries of knowledge’ – Wisbusiness.com

MADISON Six University of Wisconsin-Madison faculty have been elected to the American Academy of Arts and Sciences.

Bioethicist R. Alta Charo, psychologist Seth Pollak, philosopher Steven Nadler, historian Louise Young, geographer Lisa Naughton and chemist Martin Zanni are among the 276 new members announced April 23. Election to the academy recognizes distinguished contributions by these scholars to their fields.

Former UW-Madison Provost Sarah Mangelsdorf was also elected to the academy this year. Mangelsdorf began her tenure as president of the University of Rochester in July 2019.

Charo is the Warren P. Knowles Professor of Law and Bioethics and an expert on law and policy related to research ethics, stem cell research and new medical technology. She has served as an adviser and expert to the federal government and multiple presidential administrations on ethical concerns in cutting-edge research. And she recently co-chaired a National Academy of Sciences panel to develop recommendations around human gene editing.

Pollak is the College of Letters & Science Distinguished Professor of Psychology. At UW-Madisons Waisman Center, he researches the link between childhood stress and well-being. Pollaks team has uncovered the lasting effects of negative experiences in childhood and seeks to use this knowledge to improve the social and emotional experiences of children and the adults they become.

Nadler is the William H. Hay II Professor and Evjue-Bascom Professor in Humanities and a philosopher specializing in early modern and Jewish philosophy. He has authored 13 books, including Rembrandts Jews, a Pulitzer Prize finalist, and the graphic book, co-authored with his son Ben Nadler, Heretics!: The Wondrous (and Dangerous) Beginnings of Modern Philosophy. Nadler currently serves as director of UW-Madisons Institute for Research in the Humanities.

Young is a professor of Japanese history. Her research has covered Japan in and around the Second World War, and she has authored two books on Japans culture before and during the war. Her current book projects include a history of the countrys transition from feudal systems to a modern class hierarchy and a reexamination of Japans role in creating the modern world from the mid-19th century onward.

Naughton is a professor of geography focused on the social and political consequences of biodiversity conservation. Her research has focused on protected areas, wildlife and land use conflicts in South America, and she has studied public attitudes toward wolf recovery in the Upper Midwest. She directed UW-Madisons Land Tenure Center from 2009 to 2013 and chaired the Nelson Institutes graduate program in Conservation Biology and Sustainable Development from 2007 to 2010.

Zanni is the V.W. Meloche-Bascom Professor of Chemistry. Using an innovative method known as two-dimensional spectroscopy, the Zanni lab studies topics in biophysics and the energy sciences. They have researched carbon nanotube energy transfer, solar cell charge transfer, and the ways in which protein aggregations lead to diseases such as Type 2 diabetes and cataracts. Zanni was elected a fellow of the American Physical Society in 2010.

The news that six colleagues are new members of the American Academy of Arts and Sciences is further evidence for a fact: Faculty at UW-Madison are extraordinary, says UW-Madison Provost Karl Scholz. We congratulate these six for this wonderful recognition and thank them, and all in the UW-Madison community, for relentless efforts to expand the boundaries of knowledge and understanding of the human condition.

The academy was formed in 1780 to honor exceptional individuals and engage them in advancing the public good. Members have included Benjamin Franklin, Alexander Hamilton, Margaret Mead and Martin Luther King Jr. This years new members include former Attorney General Eric Holder, author Ann Patchett and filmmaker Richard Linklater.

Read this article:
UW-Madison: Academy adds new members from UW who 'expand the boundaries of knowledge' - Wisbusiness.com

Global Cell Sorting Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025 – Bandera County Courier

A new research study titled Global Cell Sorting Market Report 2020, Forecast to 2025 has been presented by Magnifier Research which offers a comprehensive analysis on the market. Users can benefit from this complete market research report with all the required useful information about this market. The report covers the important components related to the top sellers of the global Cell Sorting industry that influence the market. However, it inspects the primary formats changing the dynamics of the market. Likewise, it covers related current affairs, which will be influencing the market. What more, it simplifies the essential sections and also the sub-sections that represents the recent zone.

Key Components Covered in The Report:

The research document is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments. The report further estimates the global Cell Sorting industry esteem chain, powerful business strategies, cost, structure, creation limit, conveyance, market range, and limits usage rate. The market provides basic information of market members and organizing profiling, contact data, item/benefit beds, income development, revenue generation, and gross deals. This study also provides sales, revenue, and market share for each player covered in this report for a period between 2015 and 2020.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/37752/request-sample

Following are the topmost key players covered in this global Cell Sorting market research report:- NanoCellect Biomedical, Innovative Biochips, Cesca Therapeutics, Fluidigm, LumaCyte, Union Biometrica, LevitasBio, RareCyte, Cytonome, Namocell, STEMCELL Technologies, Akadeum Life Sciences

Together with geography at the worldwide forecast to 2025 is just absolutely professional and thorough. Moreover, the research study lists the major regional countries, focusing on the remarkable regions:- North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).

The market segment based on product type includes:- Cancer Cell, Immune Cells, Microbial Cell, Red Blood Cell/Platelet, Stem Cell, Other

Applications mentioned in this report:- Cell Research, Biomedical Diagnosis, Other

Furthermore, the global Cell Sorting market has been divided into types, applications, and regions. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market. The report further includes market shares for 2015 and 2025, for each of the above-mentioned segments. It also highlights the export and import of the market. It also analyses the regional distribution of the industry in terms of development trends.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-cell-sorting-market-report-2020-forecast-to-37752.html

Points Covered In This Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@magnifierresearch.comWeb: http://www.magnifierresearch.com

Read more:
Global Cell Sorting Market 2020 Industry Analysis by Manufacturers, Type, Application, End-User and Forecast 2025 - Bandera County Courier

Synthetic Stem Cells Market research by Growth, Competitive methods and Forecast to 2026 – Latest Herald

Synthetic Stem Cells Market research report enhanced worldwide COVID19 Impact analysis on Market Size (Value, Production, Sales, Consumption, Revenue, and Growth Rate), Gross Margin, Industry Chain, Trends, Top Manufacturers, Development Trends, History and 6 Year Forecast. This Synthetic Stem Cells Market competitive landscapes provides details by topmost manufactures like (North Carolina State University, Zhengzhou University) with data such as Company Profiles, Trade Sales Volume, Gross, Cost, Industry Share By Type, Product Revenue , Specifications and Contact Information. Besides, Synthetic Stem Cells industry report helps to analyse competitive developments such as Joint Ventures, Strategic Alliances, Mergers and Acquisitions, New Product Developments, Research and Developments.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Synthetic Stem Cells[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2395700

Target Audience of the Synthetic Stem Cells Market in This Study: Key Consulting Companies & Advisors, Large, medium-sized, and small enterprises, Venture capitalists, Value-Added Resellers (VARs), Manufacturers, Third-party knowledge providers, Equipment Suppliers/ Buyers, Synthetic Stem Cells market Investors/Investment Bankers, Research Professionals, Emerging Companies, Service Providers.

Scope of Synthetic Stem Cells Market:Synthetic stem cells offer therapeutic benefits comparable to those from natural stem cells and could reduce some of the risks associated with stem cell therapies. Additionally, these cells have better preservation stability and the technology is generalizable to other types of stem cells.

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Cardiovascular Diseases Neurological Disorders Other Diseases

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Cancers Wounds and Injuries Musculoskeletal Disorders Blood disorders

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2395700

Geographically, the report includes the research on production, consumption, revenue, Synthetic Stem Cells market share and growth rate, and forecast (2020-2026) of the following regions:

Key Developments in the Synthetic Stem Cells Market:

To describe Synthetic Stem Cells Introduction, product type and application, market overview, market analysis by countries, Synthetic Stem Cells market Opportunities, Market Risk, Market Driving Force;

To analyze the manufacturers of Synthetic Stem Cells market , with Profile, Main Business, News, Sales, Price, Revenue and Market Share in 2016 and 2020;

To display the competitive situation among the top manufacturers in Global, with sales, revenue and Synthetic Stem Cells market share in 2016 and 2020;

To analyze the key countries by manufacturers, Type and Application, covering North America, Europe, Asia Pacific, Middle-East and South America, with sales, revenue and Synthetic Stem Cells market share by manufacturers, types and applications;

To analyze the Synthetic Stem Cells market Manufacturing Cost, Key Raw Materials and Manufacturing Process etc.

To analyze the Industrial Chain, Sourcing Strategy and Downstream End Users (buyers);

To describe Synthetic Stem Cells market sales Channel, Distributors, Traders, Dealers etc.

To describe Synthetic Stem Cells market Research Findings and Conclusion, Appendix, Methodology and Data Source.

Contact:

ResearchMozMr. Nachiket Ghumare,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See original here:
Synthetic Stem Cells Market research by Growth, Competitive methods and Forecast to 2026 - Latest Herald

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 Industry Size, Growth, Revenue, Global Statistics and Forecast to 2026 – Cole…

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Report covers the Size, share, Growth Industry preparation models, producing method, situation and business operations of this Market. Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market industry report 2020-2026 report covers the most recent development establishing in the Market, development opportunities and situation.

Get Sample Copy @ https://www.orianresearch.com/request-sample/1479129

The report offers clearing sections of insights extracted by completely breaking down authentic and current improvements in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. It additionally gives second to none cutting edge estimations to different essential elements including Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market size, share, net profit, sales, revenue, and growth rate.

The key players covered in this study

The key players covered in this studyOrange County Hair Restoration CenterHair Sciences Center of ColoradoAnderson Center for HairEvolution Hair Loss InstituteSavola Aesthetic Dermatology CenterVirginia Surgical CenterHair Transplant Institute of MiamiColorado Surgical Center & Hair Institute

Key Points Describing Various Key Points:-

Manufacturing Analysis The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market gives a section featuring manufacturing process investigation approved by means of essential data gathered through Industry specialists and Key authorities of profiled organizations.

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Competition Leading professionals have been investigated depending on their company profile, product database, capacity, product/service value, transactions, and cost/revenue.

Demand & Supply and Effectiveness Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies report additionally provides distribution, Production, Consumption & EXIM (Export & Import).

Inquire more or share questions if any before the purchase on this report: https://www.orianresearch.com/enquiry-before-buying/1479129

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Report covers an analytical view with complete information on product representations, sales, and revenue by sector, including manufacturing cost breakdown, industrial chain, market effect factors. The Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market size will grow from USD in 2020 to USD by 2026, at estimated CAGR values.

The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies has been observing an impressive change in its size and value. The report introduces a detailed examination of the different segments and sub-sections of the market, including the product types, advancements, applications, industry verticals, and areas that are relied upon to command the Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market during the estimated forecast period.

Key Focused Regions in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market:

South America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market (Brazil, Argentina)

The Middle East & Africa Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market (South Africa, Saudi Arabia)

Europe Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market (Spain, U.K., Italy, Germany, Russia, France)

North America Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market (U.S., Mexico, Canada)

Asia-Pacific Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market (China, Japan, India, Southeast Asia)

Order a Copy of This Report: https://www.orianresearch.com/checkout/1479129

Table of Contents Describing Detail Research Report:

1 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Overview

2 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Competition by Manufacturers

3 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Retrospective Market Scenario by Region

4 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Historic Market Analysis by Type

5 Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Historic Market Analysis by Application

6 Company Profiles and Key Figures in Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Business

7 Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Manufacturing Cost Analysis

8 Marketing Channel, Distributors and Customers

9 Market Dynamics

10 Global Market Forecast

11 Research Finding and Conclusion

12 Methodology and Data Source

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of Market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US +1 (415) 830-3727

UK +44 020 8144-71-27

Email: [emailprotected]

Follow this link:
Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market 2020 Industry Size, Growth, Revenue, Global Statistics and Forecast to 2026 - Cole...

Coronavirus Q&A: Dr. Camillo Ricordi Gives Update On Trials Of Stem Cell Treatment For Most Severe COVID-19 Cases – CBS Miami

MIAMI (CBSMiami) A team of doctors at the University of Miami is working on what could be groundbreaking therapy for treating some COVID-19 patients.

With a focus on those suffering with severe lung inflammation, theyre using the umbilical system cells to treat patients.

For an update on how its progressing, Dr. Camillo Ricordi, a University of Miami professor and stem cell therapy researcher, joined Eliott Rodriguez and Rudabeh Shahbazi via Skype.

Q: This therapy is building off a 10-patient study in China and the results of that study are limited. So what information gave you hope that this would work on a broad scale?

A: Well, the information from this initial study have been incredibly encouraging. The editor in chief of the journal that did editorial on the paper presented commented as extraordinary results, but that need to be validated by law by lots of clinical trials. So were happy that FDA approved us to do such clinical trial at the University of Miami. And the nice thing is that well have the results in a very short time because these cells is like injecting anatomy of cells, 200 million cells, into those that will be fighting the complication of the infection and will know within weeks the there is a positive effect.

Q: How many patients are in the trial? When did you start? Have you seen any results so far?

A: We did. We have 24 patients in this initial trials. We didnt start the first patient, there have been only patients that are on compassionate release so far. And the initial results are coming from China and Israel. But we are ready to go. We have the terms the six doses already ready to be delivered and other 25 doses are ready to follow. So we have over as far as cell supply for the entire clinical trial, and we hope to have results very soon.

Q: So for the layman like us, can you explain how, why the stem cells infused in a vein end up in a lung?

A: Yeah, actually, this is a nice feature because when we do these trials, I directed Diabetes Research Institute at the University of Miami, so, traditionally, we did this trial for type 1 diabetes or for kidney disease. But in this case, when you inject the cells IV, intravenously, the first filter that is the lungs. So naturally the cells are trapped by the lungs as much as 95%. So in the case of targeting the pancreas or the kidney, you have to do an interventional radiology procedure to put a catheter in there that goes to these organs. But when you target the lung, this is a natural way of delivery and these cells form naturally to the lung. In addition, the cells sense inflammation and tissue injury, and hone, they go targeting specifically the site of tissue injury and inflammation. So in this case is even more relevant that in a simple intravenous, like a blood transfusion, will exactly target the lung, that is the organ that we want to treat

Q: How long do you expect to have to wait before you know if this was working?

A: Well, we know from the radiologic examination of the lungs from the studies in China, for example, that within days a resolution of the lung pathology.

Q: What is the typical recovery rate for COVID patients who have been put on a ventilator and is that meant to treat patients before they get to that critical stage?

A: Well, the typical recovery rate that we expect with this treatment is within a week we should know. So this is not a trial that we are required, like months or years of follow up to see if there is a beneficial effect or not. We are confident that within days or a week you will know if this is working or not as soon as we start.

Q: Is this is therapy meant to complement other forms of therapy?

A: I think it will definitely be used as a combination therapy. We dont exclude any other therapy as part of the combination therapy. With another agent that may help fight this is immune reaction, this pro-inflammatory reaction and also the problem that you see in micro-thromboembolism and the coagulation problem that you see in these patients. So I think is in a way is a unique therapy because its not just for COVID-19, but its for any virus targeting the lung with this massive reaction. So it will be something that we are planning in the future to create the repository for rapid intervention and integrated response to any pandemic or a situation in which you have an emergency that you need to treat an injury to the lung of such dimension. But in the meantime, when there is not a pandemic situation, you can use these cells. We have trials ongoing that has been authorized by the FDA for type 1 diabetes, Alzheimer, for kidney disease. So its a cell type that can be used in many other situations to start normal organ function, not just COVID-19.

Q: If this succeeds, how big of a deal is it?

A: If this succeeds, it will be a way to treat the severe cases of COVID-19 while we wait for a vaccine. But also to have a repository of cells that will be able to treat any other possible pandemic or epidemic where the lung will be a target of the viral attack. In this case, you have an army of cells that are ready to be used and fight this viral infection and all the consequences that can induce in the lungs.

RELATED:Current Curfews In South FloridaDrive-Through Testing LocationsTrack The Spread Of The Coronavirus In Real TimeHow To Make Your Own Face Mask

See more here:
Coronavirus Q&A: Dr. Camillo Ricordi Gives Update On Trials Of Stem Cell Treatment For Most Severe COVID-19 Cases - CBS Miami

Vitro Biopharma Submits IND Application to FDA for AlloRx Stem Cell(R) Therapy of COVID-19 – Yahoo Finance

GOLDEN, CO / ACCESSWIRE / April 21, 2020 / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma announced the filing an investigational new drug (IND) application with the FDA for clinical use of AlloRx Stem Cells in the treatment of COVID-19 patients in the US. Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging safety and efficacy results. Seventeen critically ill patients treated with umbilical cord-derived stem cells that are comparable to AlloRx Stem Cells, responded quickly by no longer requiring ventilator assisted breathing and were discharged. Also, the Israeli firm Pluristem recently reported recovery in six patients treated with similar stem cells derived from the human placenta. Together with prior safety studies conducted by Vitro Biopharma and others, there is a strong & compelling argument to allow clinical testing of AlloRx Stem Cells for COVID-19 infections in our proposed Phase I study.

Dr. Jim Musick, Ph.D., CEO said, "We are very pleased to have submitted our IND using our expanded regulatory team, including a renown regulatory expert in FDA clinical trial management. We are establishing strong communication channels with FDA officials to facilitate and expedite review of our application as well as subsequent steps to gain full FDA approval of AlloRx Stem Cells. Several clinical centers have expressed interest in our stem cell therapy. We are also pursuing other avenues for compassionate use and the COVID-19 Treatment Plan Acceleration Program. We are confident that our therapy is safe & effective based on our prior studies and those of others. MSCs block the cytokine storm that occurs in COVID-19 patients in acute respiratory distress through their powerful anti-inflammatory effects. The cytokine storm leads to the need for assisted breathing by ventilators, transfer to ICU and tremendous burdens on the US health care system. It is important to note that AlloRx Stem Cells are therapy for other viral attacks including influenza since stem cells block acute respiratory distress and damage to other major organs including cardiovascular, pulmonary and renal systems. AlloRx Stem Cells are very likely to assist in recovery from failure of various organ systems in COVID-19 survivors"

About Vitro Biopharma:

Vitro Biopharma, for over 10 years, has supplied major biopharmaceutical firms, elite university laboratories and clinical trials worldwide with Mesenchymal Stem Cells, MSC-Grow Brand of cell culture media, various stem cell derivatives and stem cell-derived differentiated cells. We also supply primary fibroblast cells and an expanding line of cancer-associated fibroblasts (CAFs) from various tumors including lung, breast, melanoma, pancreatic and colorectal tissues. Our CAFs are purchased by major pharmaceutical and biopharmaceutical firms to advance immunotherapy of cancer.

Out of years of research, we developed our patent-pending and proprietary line of umbilical cord derived stem cells AlloRx Stem Cells now being used in offshore regenerative medicine clinical trials. Our stem cells are used in regenerative medicine clinical trials with our partner in the Cayman Islands http://www.DVCStem.com. We have a recently approved clinical trial using our AlloRx Stem Cells to treat musculoskeletal conditions at The Medical Pavilion of the Bahamas http://www.tmp-bahamas.com in Nassau.

Vitro Biopharma has a proprietary and scalable manufacturing platform to provide stem cell therapies to critically ill Coronavirus patients and other conditions including multiple sclerosis, OA, Chrohn's disease and numerous medical conditions that are under-treated by the current standard of care. Our cGMP manufacturing is ISO9001, ISO13485 certified and we are FDA registered. Our stem cells have been shown to be safe and effective in Phase I clinical trials.

CONTACT:

Dr. James MusickChief Executive OfficerVitro Biopharma(303) 550-2778 E-mail: jim@vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Story continues

See the original post here:
Vitro Biopharma Submits IND Application to FDA for AlloRx Stem Cell(R) Therapy of COVID-19 - Yahoo Finance

Live Cell Imaging Market in North America region at a CAGR of 8.9% according to a new research report – WhaTech Technology and Markets News

The Global Live Cell Imaging market to grow from USD 2.9 billion by 2023 from an estimated USD 1.9 billion in 2018, at a CAGR of 8.9%

The growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, and the growth in funding for research are the major factors driving the growth of the global live cell imaging market. However, factors such as the high cost of high-content screening systems and the shortage of skilled professionals are expected to restrain the growth of this market during the forecast period.

How much is the Live Cell Imaging Market worth?

MarketsandMarketsforecasts theLive Cell Imaging marketto grow from USD 2.9 billion by 2023 from an estimated USD 1.9 billion in 2018, at a CAGR of 8.9% during the forecast period. Factors such as the high cost of high-content screening systems and the shortage of skilled professionals are expected to restrain the growth of this market during the forecast period.

The globalLive Cell Imaging marketis segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of this market majorly due to the growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada.

The instruments segment accounted for the largest share of the market in 2018

On the basis of product and service, the global live cell imaging market is segmented into instruments, consumables, software, and services. In 2018, the instruments segment accounted for the largest share of the live cell imaging market.

Factors such as the launch of new and advanced instruments, increasing incidence of diseases, and rising government initiatives and awareness programs for promoting cell-based research are the major factors driving the demand for live cell imaging instruments.

The academic & research institutes segment is expected to grow at the highest CAGR during the forecast period

On the basis of end user, the live cell imaging market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations (CROs). The academic & research institutes segment is expected to grow at a higher CAGR during the forecast period.

The high growth in this segment can be attributed to the increasing focusing of academic and research institutes on strengthening their own drug discovery research programs coupled with rising government funding to support research and advancing scientific goals.

Download PDF Brochure atwww.marketsandmarkets.com/pdfdown=163914483

The stem cells segment is expected to grow at the fastest rate during the forecast period

On the basis of application, the live cell imaging market is segmented into cell biology, stem cells, developmental biology, and drug discovery. The stem cells segment is expected to grow at the highest CAGR during the forecast owing to the increasing stem cell research activity and investments.

North America to account for the largest market size during the forecast period.

North America is the major revenue generating region in the live cell imaging market. The live cell imaging market in the region is driven by the availability of government funding for life science research, drug development regulations, advances in live cell imaging techniques, growth in the biotechnology and pharmaceutical industries, and the rising incidence of cancer.

Report:www.marketsandmarkets.com/request=163914483

Who are the leading vendors operating in Live Cell Imaging Market?

Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc.

(US), Sartorius AG (Germany), BioTek Instruments (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), and NanoEnTek Inc.

(Korea).

Danaher dominated the live cell imaging market in 2017. The company is a global leader in live cell imaging and has been operating in the market for about 50 years.

Innovation is the prime strength of the company, on the basis of which, Danaher has been able to expand its product portfolio, enter new markets, and build a better network for increasing its customer base.

Report: http://www.marketsandmarkets.com/speakto=163914483

This email address is being protected from spambots. You need JavaScript enabled to view it.

Read more:
Live Cell Imaging Market in North America region at a CAGR of 8.9% according to a new research report - WhaTech Technology and Markets News

Stem Cell Cartilage Regeneration Market Share Analysis and Research Report by 2025 – Express Journal

Growth Analysis Report onStem Cell Cartilage Regeneration Market size | Industry Segment by Applications (Hyaline Cartilage, Fibrocartilage and Other), by Type (Cell Based Approaches and Non-cell Based Approaches), Regional Outlook, Market Demand, Latest Trends, Stem Cell Cartilage Regeneration Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report titled, Stem Cell Cartilage Regeneration market has adopted an organized way to evaluate the dynamics of the overall market. It provides a comprehensive Stem Cell Cartilage Regeneration market analysis comprising of a top-to-bottom research on the market dynamics, including Stem Cell Cartilage Regeneration market growth drivers, challenges, threats, and potential growth opportunities, with a key focus on not only the global market but also the regional market. In a chapter-wise format, the Stem Cell Cartilage Regeneration market share report evaluated the global supply and demand trends in the market, including the significant insights and graphical representation.

The report provides data taking into attention the latest advancements in the global Stem Cell Cartilage Regeneration Market while appraising the impact in the Stem Cell Cartilage Regeneration market of the most important players in the near future.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/59027

Some of the Major Stem Cell Cartilage Regeneration Market Players Are:

Brief of the competitive landscape

The Stem Cell Cartilage Regeneration market report consists of a brief of the competitive terrain of this industry. The study specifies an Stem Cell Cartilage Regeneration Market analysis of the competitive scope in the competitive landscape. Data related to the participants of the industry along with its current share in the Stem Cell Cartilage Regeneration market, area served as well as production sites is involved in the report.

Along with that, details regarding companys product portfolio, products application areas, as well as features of the product has been presented in the research study of Stem Cell Cartilage Regeneration Market report. Information about the profiles of the companies as well as data related to their profit margins and models is also induced in the report.

Stem Cell Cartilage Regeneration Market Outlook by Applications:

Stem Cell Cartilage Regeneration Market Statistics by Types:

The research report studies the historical, present, and future performance of the Stem Cell Cartilage Regeneration market. The report further evaluates the present competitive landscape, prevalent business models and the possible advancements in offerings by significant players of Stem Cell Cartilage Regeneration market in the up-coming years.

Key highlights of the Stem Cell Cartilage Regeneration market report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/59027

Read more:
Stem Cell Cartilage Regeneration Market Share Analysis and Research Report by 2025 - Express Journal